USFDA completes inspection of Lupin’s Pithampur facility
12th Feb 2020

United States Food and Drug Administration (USFDA) has completed inspection at Lupin’s Pithampur unit-1 facility. The inspection was carried out between February 3, 2020 and February 11, 2020. The inspection for the Pithampur unit-1 facility closed with two 483 observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.